lobbying_activities: 3489834

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3489834	95bf23ef-8529-45b1-8fd7-dc82b57da733	Q4	E3 STRATEGIC CONSULTING GROUP	401104104	PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION	2025	fourth_quarter	PHA	Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues, pharmacy benefit managers transparency issues, Intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act;" S. 3345 - "PBM Price Transparency and Accountability Act."	HOUSE OF REPRESENTATIVES,SENATE	50000		0	0	2026-01-16T14:39:06-05:00